Advanced in Dementia

Dr. William J. Burke

Psychiatry
988102 Nebraska Medical Ctr, 
Omaha, NE 
Accepting New Patients
Advanced in Dementia
988102 Nebraska Medical Ctr, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Burke is a Psychiatrist in Omaha, Nebraska. Dr. Burke is rated as an Advanced provider by MediFind in the treatment of Dementia. His top areas of expertise are Dementia, Alzheimer's Disease, and Major Depression. Dr. Burke is currently accepting new patients.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 17 articles and participated in 7 clinical trials in the study of Dementia.

Specialties
Psychiatry
Licenses
Geriatric Psychiatry in NE
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

988102 Nebraska Medical Ctr, Omaha, NE 68198

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 26, 2022
Intervention Type: Drug
Study Drug: Tilavonemab
Study Phase: Phase 2
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

21 Total Publications

Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Journal: International psychogeriatrics
Published: April 17, 2023
Similar Doctors
Distinguished in Dementia
Dr. Thomas M. Magnuson
Psychiatry | Geriatrics
Distinguished in Dementia
Dr. Thomas M. Magnuson
Psychiatry | Geriatrics

Psychiatric Services PC

9239 W Ctr Rd, Suite 211, 
Omaha, NE 
 (4.5 miles away)
402-399-9305
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Magnuson is a Psychiatrist and a Geriatrics provider in Omaha, Nebraska. Dr. Magnuson is rated as an Advanced provider by MediFind in the treatment of Dementia. His top areas of expertise are Dementia, Vascular Dementia, Major Depression, and Cerebellar Degeneration. Dr. Magnuson is currently accepting new patients.

Distinguished in Dementia
Dr. Rebecca M. Wester
Family Medicine | Psychiatry | Geriatrics
Distinguished in Dementia
Dr. Rebecca M. Wester
Family Medicine | Psychiatry | Geriatrics

Homaha Senior Care LLC

1540 N 72nd St, 
Omaha, NE 
 (2.9 miles away)
402-393-6500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rebecca Wester is a Psychiatrist and a Geriatrics provider in Omaha, Nebraska. Dr. Wester is rated as an Advanced provider by MediFind in the treatment of Dementia. Her top areas of expertise are Dementia, Necrosis, Cerebellar Degeneration, and Muscle Atrophy. Dr. Wester is currently accepting new patients.

Advanced in Dementia
Dr. Rajesh R. Tampi
Psychiatry
Advanced in Dementia
Dr. Rajesh R. Tampi
Psychiatry

Alegent Creighton Health

7101 Newport Ave, 
Omaha, NE 
 (5.1 miles away)
402-572-2905
Languages Spoken:
English, Hindi, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajesh Tampi is a Psychiatrist in Omaha, Nebraska. Dr. Tampi is rated as an Advanced provider by MediFind in the treatment of Dementia. His top areas of expertise are Bipolar Disorder (BPD), Seasonal Affective Disorder (SAD), Major Depression, and Dementia. Dr. Tampi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Burke's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile